ArticleMolecular vision2008
Molecular analysis of the PAX6 gene in Mexican patients with congenital aniridia: report of four novel mutations.
Article in Molecular vision, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- A NovelJournal of personalized medicine · 2023Article
- Extension of the mutation spectrum of PAX6 from three Chinese congenital aniridia families and identification of male gonadal mosaicism.Molecular genetics & genomic medicine · 2018Article
- Two Paired Box 6 mutations identified in Chinese patients with classic congenital aniridia and cataract.Molecular medicine reports · 2018Article
- Morphogenetic defects underlie Superior Coloboma, a newly identified closure disorder of the dorsal eye.PLoS genetics · 2018Article
- Assessment of PAX6 alleles in 66 families with aniridia.Clinical genetics · 2016Article
- DNA-mediated cooperativity facilitates the co-selection of cryptic enhancer sequences by SOX2 and PAX6 transcription factors.Nucleic acids research · 2015Article
- A novel duplication in the PAX6 gene in a North Indian family with aniridia.International ophthalmology · 2014Article
- Molecular analysis of the PAX6 gene for congenital aniridia in the Korean population: identification of four novel mutations.Molecular vision · 2012Article
- Absence of mutations in four genes encoding for congenital cataract and expressed in the human brain in Tunisian families with cataract and mental retardation.BMC ophthalmology · 2011Article
- A [c.566-2A>G] heterozygous mutation in the PAX6 gene causes aniridia with mild visual impairment.Eye (London, England) · 2011Article
- Mutation spectrum of PAX6 in Chinese patients with aniridia.Molecular vision · 2011Article
- PAX6 analysis of one family and one sporadic patient from southern China with classic aniridia.Molecular vision · 2011Article
- TNFRSF11B computational development network construction and analysis between frontal cortex of HIV encephalitis (HIVE) and HIVE-control patients.Journal of inflammation (London, England) · 2010Article
- A novel mutation of PAX6 in Chinese patients with new clinical features of Peters' anomaly.Molecular vision · 2010Article
- Eye anomalies and neurological manifestations in patients with PAX6 mutations.Molecular vision · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePaired box gene 6 (PAX6) heterozygous mutations are well known to cause congenital non-syndromic aniridia. These mutations produce primarily protein truncations and have been identified in approximately 40%-80% of all aniridia cases worldwide. In Mexico, there is only one previous report describing three intragenic deletions in five cases. In this study, we further analyze PAX6 variants in a group of Mexican aniridia patients and describe associated ocular findings.
methodsWe evaluated 30 nonrelated probands from two referral hospitals. Mutations were detected by single-strand conformation polymorphism (SSCP) and direct sequencing, and novel missense mutations and intronic changes were analyzed by in silico analysis. One intronic variation (IVS2+9G>A), which in silico analysis suggested had no pathological effects, was searched in 103 unaffected controls.
resultsAlmost all cases exhibited phenotypes that were at the severe end of the aniridia spectrum with associated ocular alterations such as nystagmus, macular hypoplasia, and congenital cataracts. The mutation detection rate was 30%. Eight different mutations were identified: four (c.184_188dupGAGAC, c.361T>C, c.879dupC, and c.277G>A) were novel, and four (c.969C>T, IVS6+1G>C, c.853delC, and IVS7-2A>G) have been previously reported. The substitution at position 969 was observed in two patients. None of the intragenic deletions previously reported in Mexican patients were found. Most of the mutations detected predict either truncation of the PAX6 protein or conservative amino acid changes in the paired domain. We also detected two intronic non-pathogenic variations, IVS9-12C>T and IVS2+9G>A, that had been previously reported. Because the latter variation was considered potentially pathogenic, it was analyzed in 103 healthy Mexican newborns where we found an allelic frequency of 0.1116 for the A allele.
conclusionsThis study adds four novel mutations to the worldwide PAX6 mutational spectrum, and reaffirms the finding that c.969C>T is one of the three more frequent causal mutations in aniridia cases. It also provides evidence that IVS2+9G>A is an intronic change without pathogenic effect.
Indexed as
Identifiers
18776953PMC2530489W2170890770What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.